Loading...
Loading...
Orexigen Therapeutics
OREX achives FDA Advisory Board approval for their anti-obesity drug Contrave. PharmaDirections has been Orexigen's pharmaceutical development partner and has developed and produced the first Contrave product to undergo full clinical development.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in